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Background: Abnormal activation of endochondral bone formation in soft tissues causes significant medical diseases
associated with disability and pain. Hyperactive mutations in the bone morphogenetic protein (BMP) type 1 receptor
ACVR1 lead to fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive ossification
in soft tissues. However, the specific cellular mechanisms are unclear. In addition, the difficulty obtaining tissue samples
from FOP patients and the limitations in mouse models of FOP hamper our ability to dissect the pathogenesis of FOP.
Methods: To address these challenges and develop a “disease model in a dish”, we created human induced pluripotent
stem cells (iPS cells) derived from normal and FOP dermal fibroblasts by two separate methods, retroviral integration or
integration-free episomal vectors. We tested if the ability to contribute to different steps of endochondral bone formation
was different in FOP vs. control iPS cells.
Results: Remarkably, FOP iPS cells showed increased mineralization and enhanced chondrogenesis in vitro. The
mineralization phenotypes could be suppressed with a small-molecule inhibitor of BMP signaling, DMH1. Our results
indicate that the FOP ACVR1 R206H mutation favors chondrogenesis and increases mineral deposition in vitro.
Conclusions: Our findings establish a FOP disease cell model for in vitro experimentation and provide a proof-of-concept
for using human iPS cell models to understand human skeletal disorders.
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Endochondral ossificationBackground
Tissue mineralization is one of the most dramatic transi-
tions in normal development and disease. Hard tissues,
such as bone and teeth, maintain body structure, protect
vital organs, and facilitate eating. Abnormal activation
of endochondral bone formation in soft tissues from
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distribution, and reproduction in any mediumprogressiva (FOP; OMIM #135100) or from trauma or
central nervous system injury [1] cause severe disability
and pain. Although bone morphogenetic proteins
(BMPs) are key regulators of osteogenesis [2] and are
implicated in pathologic calcification [3], their specific
functions in humans are not well understood. Human
induced pluripotent stem cells (iPS cells) derived from
patients with genetic mutations affecting key signaling
pathways provide a unique opportunity to dissect human
development and disease pathogenesis in models amen-
able to experimental manipulation [4].
FOP is a rare but debilitating disease of heterotopic
bone formation associated with mutations in the Activin
A Type I receptor (ACVR1) [5], which is activated by
BMPs. A single amino acid change (R206H) commonlyntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Summary of the FOP and control human dermal fibroblasts and iPS cell lines
used in this study, including naming, classification (control vs. FOP), and
original tissue source. HDF, human dermal fibroblast; FF, foreskin fibroblast.
Please see Additional file 1: Table S1 for a detailed summary of the iPS cell
characterization. Method of making iPS cells: *, Retroviral OSKM ; **, Epi(Y4).
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in the majority of FOP patients and can increase sensitivity
of the receptor to BMP ligands [6]. Patients are born with-
out heterotopic ossification yet characteristically form large
amounts of bone either spontaneously or after trauma [7].
The heterotopic ossification follows an endochondral bone
formation pathway that starts with a pre-cartilaginous
fibro-proliferative anlage and eventually mineralizes. The
ferocity of these episodes makes it nearly impossible to ob-
tain tissue samples prospectively and significantly compli-
cates surgical management.
Here, we created a series of iPS cells from dermal fi-
broblasts of donors with FOP by either DNA-integrating
retroviral or integration-free episomal plasmid methods
[4,8]. The FOP iPS cells showed increased mineral de-
position and chondrogenesis, potentially reflecting a pre-
disposition towards endochondral bone formation in
FOP. Our findings provide a valuable foundation for hu-
man stem cell-based systems to delineate the mecha-
nisms of normal and pathologic skeletal formation.
Materials and methods
Cell culture
Primary human dermal fibroblasts (HDFs) from commer-
cial sources or from 3-mm skin biopsies carefully obtained
from donors (without causing deep tissue injury) or from
surgical excess were cultured [9] and are described in
Table 1 and Additional file 1: Table S1. HDFs less than five
passages old were used for iPS cell reprogramming. Pres-
ence or absence of the ACVR1 mutation was sequenced
and verified as described [5]. Primary human mesenchy-
mal stem cells (hMSCs) were prepared from iliac bone as
described previously [10] and expanded as a monolayer.
Retroviral [4] and episomal integration-free [8] iPS cells
were derived as described. H9 human embryonic stem
(ES) cells were from WiCell Research Institute (Madison,
WI). All pluripotent cell lines were maintained in mTeSR1
medium (StemCell Technologies, Vancouver, Canada) on
growth-factor-reduced Matrigel (BD Biosciences)-coated
plates (150–300 μg/ml, 30 min coating) or in primate ES
cell medium (ReproCELL, Tokyo, Japan) on mitomycin C-
treated or irradiated SNL feeder cells [11]. SNLs were
carefully removed by at least one passage in feeder-free
conditions before use in differentiation assays. The ROCK
inhibitor Y-27632 (10 μM, Tocris Bioscience, Minneapolis,
MN) dissolved in DMSO was added to mTeSR1 at passa-
ging and removed the following day. Karyotyping was
done by Cell Line Genetics (Madison, WI) or Nihon Gene
Research Laboratories (Sendai, Japan). Cells exposed to re-
combinant BMP4 protein (R&D Systems, Minneapolis,
MN) were treated for 45 minutes.
All human tissue collection, human stem cell studies,
procedures, and written consents were approved by the
UCSF Committee on Human Research, the UCSF Gamete
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Ethics Committee of the Department of Medicine and
Graduate School of Medicine, Kyoto University.
Embryoid body formation
Embryoid bodies (EBs) were formed from iPS cells or hu-
man ES cells once their cultures reached 80% confluence.
After washing with PBS, Accutase (StemCell Technolo-
gies, Vancouver, Canada) was applied for two minutes
to remove cells from the plate. Cells were centrifuged at
175 × g for two minutes and then resuspended in a
4:1 mix of EB differentiation medium (80% Knockout
DMEM, 20% FBS, 1% Glutamax, 1% non-essential amino
acids, and 0.1 mM 2-mercaptoethanol) and mTeSR1, and
supplemented with 10 μM Y-27632. Cells were plated onto
ultra-low attachment plates without medium changes for
seven days. On day eight, EBs were collected and allowed
to settle in a conical tube for 30 minutes. The mixed
medium was removed and replaced with 100% EB differenti-
ation medium (Knockout DMEM supplemented with 20%
FBS, 1% Glutamax, 1% non-essential amino acids, and
0.1 mM 2-mercaptoethanol) changed every three to four
days. EBs were then transferred to gelatinized plates and cul-
tured until day 15 for RNA collection in Trizol (Invitrogen).
Teratoma formation
iPS cells grown in six-well Matrigel-coated plates to
100% confluence were released with Accutase for 30
secs, rinsed twice with PBS, and resuspended in mTeSR1
supplemented with 10 μM Y-27632. Cells (1 × 106 in
20 μl) were injected into 8–14 week-old male CB17
SCID mice (Charles River) under the testis capsule as
described [4]. A minimum of six testes were injected per
iPS cell line. Tumors were collected 8–12 weeks after in-
jection, fixed with 10% neutral buffered formalin for
24 hours, and processed for paraffin-embedded sections
the Gladstone Histology and Microscopy Core or at the
Division of Technical Support of the Institute for Fron-
tier Medical Sciences in Kyoto University. All mouse
studies were approved by the UCSF Institutional Animal
Care and Use Committee, or performed in strict accord-
ance with the Regulations on Animal Experimentation at
Kyoto University.
Mineralization assay
Primary human MSCs were cultured in OB mineralization
medium (DMEM with 20% FBS, glycerol-2-phosphate,
4 μM dexamethasone, 0.1 mM 2-mercaptoethanol, and
50 μg/ml L-ascorbic acid 2-phosphate sesquimagnesium
salt hydrate [12]). We could detect mineralization activity
after 12 days as increased black staining by von Kossa
(Additional file 2: Figure S1B), which was the preferred
staining method used because the black mineralization
nodules could be easily distinguished from the expectedlight golden-yellow staining of the cell layer. Human iPS
cells maintained in feeder-free conditions were plated in
20% mTeSR1 mixed with 80% OB mineralization medium
and Y-27632 (10 μM) at 2 million, 400,000, or 37,500
cells per well of gelatin-coated 6-, 24-, or 96-well
plates, respectively. Medium was replaced on day two
with 100% OB mineralization medium and changed
every other day. Samples for von Kossa staining were
fixed in 4% paraformaldehyde (PFA), stained in 5% sil-
ver nitrate for 15 minutes, and developed in 5% sodium
carbonate/9.25% formaldehyde for two minutes. Re-
gions of increased mineralization (dark black staining)
can be seen at the edges of the well, where the culture
surface meets the well wall. This was observed for all
cell types and was excluded from staining intensity ana-
lysis. ImageJ (ver. 1.44o) was used for staining intensity
analysis [13]. DMH1 (4-[6-[4-(1-Methylethoxy)phenyl]pyr
azolo[1,5-a]pyrimidin-3-yl]-quinoline; from Dainippon-
Sumitomo Pharma or Nacalai Tesque, Tokyo, Japan) was
used at indicated concentrations; levels above 10 μM
caused cell death. Scanning electron microscopy was per-
formed on an Olympus TM3000 scanning electron micro-
scope by the Gladstone Microscopy Core.
Chondrogenic differentiation
Pellet chondrogenic cultures were performed as described
[14]. Briefly, human iPS cells collected with a scraper were
suspended as clumps in EB formation medium (DMEM,
10% Knockout Serum Replacement (KSR, Invitrogen),
10% FBS) and cultured for seven days on non-adherent
bacterial petri dishes. The medium was changed every
three days. EBs were landed onto 10-cm gelatin-coated
tissue-culture dishes, grown to confluence, released with
0.25% trypsin/EDTA, filtered through a 70-μm cell
strainer, and seeded onto new gelatin-coated dishes. Once
confluent, cells were collected and 2.5 × 105 cells were
placed into a 15-ml polypropylene tube, centrifuged at
1200 rpm for three min, and re-suspended in chondro-
genic medium (high-glucose DMEM, with human 10 ng/
ml TGF-β3, 100 nM dexamethasone, 6 μg/ml insulin,
100 μM ascorbic acid 2-phosphate, 1 mM sodium pyru-
vate, 6 μg/ml transferrin, 0.35 mM proline, and 1.25 mg/
ml bovine serum albumin). Cells were re-centrifuged and
maintained as a small pellet in the conical tubes for 28 days
with medium changes every three days. Glycosaminogly-
can content was quantified with BLYSCAN Dye and Dis-
sociation reagents (BIOCOLOR, Belfast, UK). DNA
content was quantified using a PicoGreen dsDNA quanti-
tation kit (Invitrogen).
RT-PCR and quantitative PCR expression analysis
Semi-quantitative reverse transcription expression analysis
of endogenous pluripotency genes, persistent expression
of the retroviral iPS cell induction factors, episomal
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DNase-treated RNAs with the primers and PCR condi-
tions as described [4,8]. Quantitative PCR reactions were
performed using 10 ng of reverse-transcribed cDNA in a
final volume of 5 μl with ABI’s TaqMan Universal PCR
Master Mix (Life Technologies) or ABI’s Syber Green PCR
Master Mix at the recommended reagent ratios with the
primers or probesets listed in Additional file 3: Table S2.
Each reaction was run in technical triplicates on an Ap-
plied Biosystems 7900HT or Viia7 thermocycler (Life
Technologies) and normalized to GAPDH as an endogen-
ous control using protocols recommended by ABI.
Immunocytochemistry
Cells or EBs were fixed with 4% PFA/PBS for 10 min at
room temperature, permeabilized with PBS/0.1% Triton
X-100 for 10 min at room temperature, then blocked with
1% BSA. Representative lineages were detected with the
following primary antibodies: SSEA3 (0.5 μg/ml, eBios-
ciences), TRA-1-60 (0.5 μg/ml, eBiosciences), TRA-1-81
(0.5 μg/ml, eBiosciences), NANOG (2 μg/ml, AF1997,
R&D Systems), βIII-TUBULIN (1:100, MAB1637, Milli-
pore), glial fibrillary acidic protein (1:500, Z0334, DAKO),
α-smooth muscle actin (pre-diluted, N1584, DAKO), α-
fetoprotein (2 μg/ml, MAB1368, R&D Systems), and tyro-
sine hydroxylase (1:100, AB152, Chemicon). Secondary
antibodies were obtained from Invitrogen: Alexa488 or
555-conjugated goat anti-mouse IgG (1:200), Alexa488 or
555-conjugated goat anti-rabbit IgG (1:200), and Alexa488
or 555-conjugated donkey anti-goat IgG (1:200). Nuclei
were stained with DAPI in the Vectashield set (Vector
Laboratories).
Statistical analysis
Because each iPS cell line was derived clonally, and thus
may display different behaviors, we treated each cell line
as an individual biological replicate and pooled our re-
sults into controls or FOP categories. p values were cal-
culated using the Student’s t-test or Dunnett multiple
comparisons t-test. p values ≤ 0.05 were considered sta-
tistically significant.
Results
ACVR1 R206H mutation is not sufficient to induce
mineralization of fibroblasts
FOP patients show dramatic heterotopic bone formation
in their soft tissues, yet do not ossify their skin. We
asked if the ACVR1 R206H mutation [6] could induce
mineralization in primary cells that do not normally
form bone. Human dermal fibroblasts (HDFs) from con-
trol donors without known skeletal disease and FOP do-
nors were cultured, genotyped (Additional file 2: Figure
S1A), and propagated in HDF maintenance medium. For
our mineralization assays, we used a culture medium thatdid not contain any exogenous BMPs that might mask
the effects of the ACVR1 R206H mutation. This medium
still promoted mineralization in primary human MSCs
(Additional file 2: Figure S1B) when compared with stand-
ard non-mineralizing MSC maintenance medium. How-
ever, FOP HDFs showed no differences in mineralization
activity when compared to HDFs cultured in non-
mineralizing HDF maintenance medium, even with an
additional 6 days of culture (Additional file 2: Figure S1C)
and despite detectable increases in BMP-related phospho-
SMAD levels in FOP HDFs (data not shown). Thus, the
ACVR1 R206H mutation was not sufficient to induce
spontaneous mineralization in HDFs in vitro.
Human iPS cells with the ACVR1 mutation are pluripotent
Isolating primary tissues from FOP patients is extremely
difficult since injuries, including surgical procedures, in-
duce bone formation flares. iPS cells derived from a small
skin biopsy or excess surgical material provide a potential
way to create a continuous supply of diseased tissues
in vitro for experimentation. Since BMPs induce human
ES cell differentiation [15], activated BMP signaling by the
R206H ACVR1 mutation could adversely affect our ability
to create FOP iPS cells. Fortunately our standard iPS cell
culture media (mTeSR1) is free of BMPs, thus minimizing
the potential activation of the hypersensitive R206H
ACVR1 receptor by low levels of BMP.
We first created iPS cell lines from banked FOP skin fi-
broblasts (FOP1 and FOP2). Retroviruses with OCT4, SOX2,
KLF4, and C-MYC [4] were transfected into two control and
two FOP fibroblast lines. We found a significant number of
alkaline phosphatase-positive ES cell-like colonies from the
FOP fibroblasts. Two control iPS cell lines (vWTa and
vWTb) and four FOP iPS lines (vFOP1-1, vFOP1-4,
vFOP2-1, and vFOP2-2) were characterized in detail and
showed the expected genotypes (Figure 1A-D). All of the
retroviral iPS cell lines suppressed the C-MYC and OCT3/4
transgenes (Figure 1E). Although low levels of exogenous
KLF4 and SOX2 were detected in some lines, the iPS
cell lines still expressed genetic markers of pluripotency
(Figure 1F) and could form all three germ layers in terato-
mas (Figure 1G, Additional file 4: Figure S2A) and in EBs
(Additional file 4: Figure S2B). While large amounts of cartil-
age were evident in several of the teratomas derived from
FOP iPS cells, comparing the skeletal elements was not pos-
sible because of the heterogeneity of the internal structures,
overall sizes, and maturity of each individual tumor, even
from those derived from the same iPS cell line. All lines
retained normal karyotypes (data not shown).
Retroviral FOP iPS cells show a trend to increased
mineralization
Since FOP patients develop heterotopic endochondral
bone formation, we tested if FOP and control iPS cells
Figure 1 Characterization of retroviral iPS cell lines. (A) Representative photos of FOP fibroblasts. (B) Subsequent retroviral iPS cell colonies
on mouse feeder cells (colony indicated by dashed circle). (C) Retroviral iPS cell colonies after transition to feeder-free conditions. Black scale
bar = 50 μm. (D) Retroviral iPS cell lines are heterozygous for the ACVR1 R206H (617 G > A) mutation. Control lines vWTa and vWTb1 showed a
wildtype ACVR1 gene. (E) The OCT3/4 and C-MYC retroviral transgenes are silenced in the human iPS cells, but KLF4 and SOX2 show detectable
levels of expression in some lines. (F) Pluripotent iPS cells show higher expression of pluripotency markers TERT and NANOG as compared to
differentiated cultures (15-day-old EBs). Gene expression is normalized to GAPDH and relative to H9 differentiated EB levels. Error bars are average
expression +/− 1 SD of technical triplicates. Gene expression studies were repeated in triplicate. (G) Teratoma images showing representative
tissues from all three germ layers. Yellow scale bar = 200 μm.
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in vitro. Retroviral FOP iPS cells cultured in mineralizing
conditions showed a modest trend (p = 0.15 at 15 days) to-
wards increased mineralization as assessed by von Kossa
staining (Figure 2A-B). Using electron microscopy, we
confirmed the presence of collagen-like fibers embedded
in the mineral (Figure 2C-D), suggesting that the increased
mineralization detected by von Kossa was not due tosimple calcium/phosphate precipitation that can occur
in cultured cell models [16]. qPCR of the mineralizing
iPS cells showed minimal changes in the expression
of RUNX2, OSX, and OC in FOP and control iPS cells
(Figure 2E), consistent with the relatively mild increase in
mineralization. Thus, the vFOP iPS cells showed a trend
towards increased mineral deposition by histology staining
but surprisingly mild changes in gene expression patterns.
Figure 2 Increased mineralization in retroviral FOP iPS cells. (A) von Kossa staining of retroviral control and vFOP1 and vFOP2 iPS cells after
culture in mineralizing conditions. Mineral is detected as black staining by von Kossa. (B) Quantitation of mineralization intensity. Error bars
represent the average of the two control or four FOP iPS lines, with at least three replicates at each time, +/− 1 SEM. (C, D) Electron microscopy
of day 24 mineralization cultures from vWTb or vFOP1-4 iPS cells showing collagen-like fibers (c) embedded within the mineralizing matrix (m).
Scale bar = 500 nm. (E) Quantitative PCR expression analysis of the mineralizing cultures. Two control and three FOP lines were pooled together
for the expression analysis from triplicates for each time point. Error bars represent average expression +/− 1 SEM.
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cells has been reported and may be associated with partial
reprogramming [17]. To test if the ACVR1 R206H muta-
tion favored iPS cells that retained expression of the indu-
cing transgenes, and thus created partially-reprogrammed
cells that were unable to fully show an osteogenic pheno-
type, we derived a second cohort of retroviral FOP iPS cell
lines from fresh HDFs carefully isolated from two add-
itional FOP patients (FOP4 and FOP5; Figure 3A-C). We
used the vWT-TIG120-4f1, vWT-201B2, and vWT-201B7
iPS cell lines [4,18] (here, preceded by vWT- for clarity) as
controls. In this additional cohort, OCT3/4, SOX2, and
KLF4 transgene expression was suppressed (Figure 3D),
although a very faint band of C-MYC could be detected
in vFOP4-1 by RT-PCR. However, quantitative PCR
for transgene expression showed significant silencing of all
transgenes relative to fibroblasts transduced with retro-
virus (Additional file 5: Figure S3A). The vFOP4-1,
vFOP4-3, and vFOP5-22 lines also formed teratomas con-
taining all three germ layers (Additional file 5: Figure
S3B), had normal karyotypes (Additional file 5: Figure
S3C), expressed markers of pluripotency (Additional file 5:
Figure S3D), and retained the ACVR1 R206H (617G >A)
mutation (Figure 3C). Furthermore, differentiation of
the iPS cells in the same mineralizing conditions used
previously showed increased mineralization by histology
(Figure 3E, F) and a similar gene expression pattern(Additional file 5: Figure S3E) as seen in the first cohort of
retroviral iPS cells. Treating vFOP4-1 and vFOP5-22
iPS cells with the BMP signaling inhibitor DMH1 [19,20]
during culture could block the mineralization phenotype
(Figure 3G, H).
FOP iPS cells show increased chondrogenesis
Since the second cohort of retroviral iPS cells showed bet-
ter retroviral silencing characteristics, we used this set to
test if the FOP mutation might affect chondrogenesis in a
directed in vitro chondrogenesis assay. vFOP iPS cells cul-
tured in 3-dimensional pellet cultures supplemented with
TGF-β and dexamethasone [14] produced larger pellets
with more ECM-containing chondrocyte-like cells than
control iPS cells (Figure 4A, B). Glucose-amino-glycan
(GAG) levels were 2–3-fold higher in vFOP iPS cell chon-
drocyte pellets than in controls (not shown). The vFOP4
and vFOP5 pellets also showed higher numbers of larger
chondrocyte-like cells by morphology (Figure 4C-D). Quan-
titative PCR showed elevated mRNA levels of SOX9 and
COL2a1 (markers of immature chondrocytes) and COMP
(marker of mature chondrocytes) in the pellets (Figure 4E).
Integration-free FOP iPS cells also show increased
mineralization
Since the degree of increased mineralization varied
among the different batches of retroviral iPS cells with
Figure 3 Increased mineralization in a second cohort of retroviral FOP iPS cells. (A, B) Representative photos of control and vFOP4 iPS cell
colonies on feeders after retroviral iPS cell generation. White scale bar = 200 μm. (C) Retroviral iPS cell lines vFOP4-1, vFOP4-3, and vFOP5-22
show the ACVR1 R206H (617G > A) mutation. (D) Retroviral transgene expression in vFOP4 and vFOP5 iPS cell lines by RT-PCR. (E) vFOP4, vFOP5,
and control iPS cells grown in mineralizing culture conditions. Mineral is detected as black staining with von Kossa. Representative images from
triplicate assays with similar results. (F) Quantitation of mineralization intensity. Error bars represent the average of the three control cell lines (H9,
vWT-TIG120-4f1, and vWT-201B7) or three vFOP iPS lines (vFOP4-1, vFOP4-3, and vFOP5-22), +/− 1 SD. n ≥ 6 measurements from per condition at
each timepoint. **, p < 0.01; ***, p < 0.001 by Student’s t-test. (G) Increased mineralization by vFOP4 and vFOP5 iPS cells after 15 days of culture
can be blocked by treatment with the BMP inhibitor DMH1. Representative experiment from triplicate assays with similar results. (H) Quantitation
of mineralization intensity after DMH1 treatment of FOP iPS cell lines. n = 3 measurements for each DMH1 concentration and timepoint. *, p < 0.05;
**, p < 0.01 by Dunnett’s multiple comparisons t-test compared to the no DMH1 treatment group.
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3E), we created integration-free iPS cells to test if retro-
viral transgenes confound our ability to detect the effects
of the ACVR1 R206H mutation. We used integration-
free episomal vectors to introduce the iPS cell trans-
formation factors SOX2, KLF4, OCT4, L-MYC, LIN28,
and p53 shRNA into control and FOP dermal fibroblasts
[8]. We included an expanded collection of control
dermal fibroblasts and FOP fibroblasts from skinremoved during a medically-necessary surgical proced-
ure (FOP3). We obtained a large number of FOP iPS cell
colonies with morphology consistent with human ES cells
(Figure 5A). Four lines from two control donors (eWT-
1323-2, eWT-1323-4, eWT-BJ2, and eWT-BJ4) and six
lines from three FOP donors (eFOP1-1, eFOP1-10,
eFOP2-3, eFOP2-8, eFOP3-2, and eFOP3-4) were charac-
terized in detail. All had normal karyotypes (Additional
file 6: Figure S4A), retained the R206H ACVR1 mutation
Figure 4 Increased chondrogenesis in vFOP iPS cells in pellet cultures. (A) Histology of chondrogenic pellets from vFOP4 and vFOP5 iPS
cells show larger chondrocytes and increased proteoglycan. Blue, alcian blue; red, nuclear fast red. Black scale bar = 200 μm; red scale bar = 50 μm.
(B) Chondrocyte pellet size (calculated volume). Error bars are averages of triplicate experiments, +/− 1 SD. (C) Cell size in the chondrogenic pellets.
Error bars are averages of triplicate experiments, +/− 1 SD. (D) Percentage of chondrocyte-like cells within a culture. Error bars are averages of triplicate
experiments, +/− 1 SD. (E) Chondrogenic (SOX9, COL2a1, and COMP) gene expression in the pellets. Error bars are averages of triplicate measurements
on individual pellets, +/− 1 SD. **, p < 0.01; ***, p < 0.001 by Student’s t-test.
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munostaining (Additional file 7: Figure S5). Five of the six
FOP lines had normal teratoma formation (Figure 5C,
Additional file 6: Figure S4B). Line eFOP2-8 lacked clear
mature endodermal elements and was excluded from fur-
ther analyses. Expression analysis suggested eFOP3-4 had
low levels of OCT4 plasmid expression; however, no
retained episomal vectors were found by genomic DNA
qPCR for the EBNA gene which is located in the episome
backbone (Additional file 6: Figure S4C, D). The FOP lines
had higher levels of phospho-SMAD 1/5/8 before and
after stimulation with BMP4 (Figure 5D), showing respon-
siveness to exogenous BMP.
eFOP iPS cells cultured in mineralization medium had
significantly increased mineralization activity at day 6 by
von Kossa staining (Figure 6A, B), but this difference
narrowed by day 12. We found no statistical difference
in wildtype ACVR1 expression even though the R206H
ACVR1 allele expression decreased significantly over the
course of the experiment (Figure 6C). ID1 and DLX5,
both activated by BMP signaling, were increased at day
6, indicating that the ACVR1 R206H mutation increasedactivation of BMP signaling (Figure 6D). Expression ana-
lysis showed a trend towards transient increases of chon-
drogenic markers COLLAGEN 2 (COL2a1) as well as
increased expression of the osteogenic marker OSTEO-
CALCIN (OC) at day 6 (Figure 6E, F). The FOP iPS cells
showed no significant increase in expression of early
markers of chondrogenesis (SOX9) or osteogenesis
(RUNX2) at the time points we assayed; in fact, levels of
these early markers were higher in control iPS cells as
compared to the FOP iPS cells (Figure 6E, F). FOP iPS
cells also showed increased expression of genes associ-
ated with mineralization activity (Figure 6F), such as al-
kaline phosphatase. In addition, we found increased
expression of TFIP11, a ubiquitously expressed gene that
suppresses chondrocytic development, may function
during the transition from a cartilage template towards
the formation of ossification centers [21] and may regu-
late tooth enamel deposition [22]. These in vitro results
suggest that the ACVR1 R206H mutation confers in-
creased propensity towards mineral deposition, possibly
via a mineralized cartilage mechanism with transient in-
creases in osteogenic markers.
Figure 5 Integration-free FOP iPS cells. (A) Representative images of FOP3 dermal fibroblasts subsequently converted to human iPS cell
colonies in feeder-free conditions. Black scale bar = 50 μm. (B) Human integration-free iPS cells from donors with FOP are heterozygous for the
ACVR1 R206H (617G > A) mutation but control lines are not. (C) Representative teratomas from one eFOP iPS cell line showing tissues representing
all three germ layers (n, neuronal/primitive neural tube like structure; c, cartilage; g, primitive gut). Additional cell lines are shown in Additional file 6:
Figure S4. Black scale bar = 50 μm. (D) Western blot showing total SMAD1/5/8 and phospho-SMAD1/5/8 (pSMAD) levels in FOP iPS cell
lines relative to control lines with (+) and without (−) 45 minutes of BMP4 exposure. GAPDH, loading control. Representative blot of
triplicate experiments.
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Here, we use human iPS cells derived from FOP donors
to establish a cellular foundation to understand the
mechanisms underlying this dramatic disease (Figure 7).
Our FOP iPS cells are a valuable in vitro human model
system for understanding how human bone develops
and identifying what control points may be amenable for
manipulating normal and pathologic bone formation.
The iPS cells will also facilitate identifying the triggers of
heterotopic bone formation and strategies to block the
different steps of mineralization or ossification, particu-
larly by providing the ability to create key human cell
types not directly available from the FOP patients or
from patient progenitor cells. These iPS cells also pro-
vide a unique human-specific perspective that comple-
ments the in vivo studies of the FOP mouse model [23].
In this study, we created and analyzed three sets of
independently-derived iPS cell lines. Our results suggest
that generating iPS cells with integration-free methods
rather than retroviral methods may decrease the likeli-
hood of confounded results from persistent transgene
expression, as has been described for C-MYC [24].
Our findings indicate that the ACVR1 R206H muta-
tion can allow human iPS cells to form chondrocytes
and mineralize in vitro without a clear fibro-proliferative
stage as in FOP patients. Since the fibro-proliferativecells in an early FOP lesion are likely a collection of di-
verse cell types, we speculate that more primitive cell
types or early skeletal precursors, such as those poten-
tially in our iPS cell model, could be major contributors
to the early FOP lesion. Although this might explain the
mineralization that occurred without altered osteogenic
markers, further experiments are needed to delineate the
distinct effects of ACVR1 R206H on mineralization and
osteogenesis in our iPS cell model.
Our results also suggest that the ACVR1 R206H mu-
tation may have greater influence earlier in endochon-
dral bone formation (i.e., at the chondrogenesis stage)
based on gene expression patterns. Although ACVR1
can be regulated by miR-148a [25], the decreasing
levels of ACVR1 R206H mRNA during mineralizing
culture suggest that the 617 G > A mutation confers
allele-specific regulation of RNA transcripts. However,
the heterogeneity of our iPS cell mineralization cultures
precluded us from identifying if a specific cell type is
down-regulating ACVR1 R206H expression during cul-
ture. Delineating this potential regulatory function
using FACS-purified cells or iPS cell-derived cell types
could identify more specific roles for ACVR1 in bone
formation and identify a new therapeutic target that
would complement strategies to modulate the signaling
properties of the ACVR1 receptor.
Figure 6 Increased mineralization capacity in integration-free FOP iPS cells. (A) eFOP iPS cells show greater mineralization than controls by
von Kossa staining. (B) Quantitation of mineralization. n = 46–51 wells for each condition, combining at least three replicates of each of the four
control iPS lines or five FOP iPS lines. Error bars, +/− 1 SD. *, p < 0.05. †, p < 0.1. (C) Quantitative PCR of ACVR1 (wildtype and R206H mutant)
during osteogenic culture. (D–F) Quantitative PCR during osteogenic culture of genes downstream of BMP signaling (ID1 and DLX5), chondrogenic
(SOX9, ACAN, COL2a1, and COMP), osteogenic (RUNX2, SP7, and OC), and mineralization (AP and TFIP11) markers. n = 3–6 samples per iPS cell line per
condition, each measured in triplicate; Error bars, +/− 1 SEM; *, p < 0.05. †, p < 0.1.
Matsumoto et al. Orphanet Journal of Rare Diseases 2013, 8:190 Page 10 of 14
http://www.ojrd.com/content/8/1/190Although we could identify differences in mineralization
by the FOP iPS cells, our simple culture conditions may
not fully recapitulate the requirements for forming mature
osteogenic cells from iPS cells. Similar challenges for cre-
ating mature cell types have been identified using current
culture methods in other types of ES or iPS cell-derived
progeny [26] and in some mesenchymal stem cell culture
conditions [27]. This could account for the low expression
levels of osteogenic genes. Instead, our culture conditions
may better reflect the early steps of matrix mineralization
in injured cartilage. The increased expression of genes
associated with mineralization activity, such as TFIP11
and alkaline phosphatase, suggest the ACVR1 R206Hmutation can direct mineral deposition in tissues. This is
consistent with reports indicating that BMP signaling in-
creases mineralization activity in other cell types [28].
Bone formation and mineralization can also occur in the
absence of osteoblasts in Osx-deficient mice [29,30].
Future studies will benefit from newer 3D scaffolds,
the creation of multi-cellular bone models with iPS cell–
derived cell types, better defined culture conditions, and
in vivo translational assays which may favor the forma-
tion of mature skeletal cells. These directions will help
identify the factors that may act at different stages of
osteogenesis, including those that initiate heterotopic
bone formation and lead to the formation of mature
Figure 7 Human iPS cells for disease modeling. Our results suggest an increased disposition towards mineralization and chondrogenesis,
consistent with modeling the early developmental and heterotopic bone formation processes. Our in vitro model will allow detailed interrogation
of the mechanisms regulating bone formation and triggers of FOP flares, potentially identifying novel treatments for treating pathologic bone
diseases.
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suggest that blocking mineralization induced by ACVR1
R206H may be a useful treatment strategy for preventing
full mineralization of heterotopic bone lesions in FOP
patients, thus preserving some limited joint mobility
even if cartilage formation still occurs.
The increased chondrogenesis and mineralization, as
well as the trend towards increased expression of endo-
thelial cell gene markers, raise the possibility that the
R206H ACVR1 mutation promotes skeletogenesis by af-
fecting cell fate. Several observations support this no-
tion. Studies in connective tissue progenitor cells from
discarded primary teeth (SHED cells) of FOP patients
with the ACVR1 R206H mutation show enhanced osteo-
genic differentiation [31]. In addition, introducing the
R206H ACVR1 mutation into endothelial cells can in-
crease endothelial-mesencymal transition and promote
entry into an osteogenic lineage [32], possibly contribut-
ing to the bone formation in FOP. Finally, BMP activa-
tion induces differentiation in human ES cells [15].
These results suggest that activating the BMP signaling
pathway may affect a cell’s ability to retain cell-fate com-
mitment under specific circumstances.Our studies showed that pluripotent FOP iPS cells can
be generated without a BMP inhibitor using either the
retrovirus or episomal methods. Prior attempts to make
iPS cells from FOP fibroblasts by the Sendai virus method
showed cellular instability [33]. This could be partially
mitigated by culturing the cells with a BMP inhibitor,
making the iPS cell formation process a useful assay for
identifying small molecules that affect ACVR1 signaling.
Although our study was not designed to directly compare
the different iPS cell-generating methods, our results iden-
tify two major implications. First, our findings suggest that
different pluripotency induction techniques, culture con-
ditions, or embryonic fibroblast feeder cells could influ-
ence the success of iPS cell generation. Although Sendi
virus can efficiently express reprogramming factors, the
steps needed to remove replicating virus from cultures
and the sensitivity of the viral RNA replicase to transgene
sequences may contribute to different overall efficiencies
of iPS cell generation [34]. Furthermore, the conditions
under which iPS cells are derived, including the specific
feeder cells used, can affect important aspects such as
gene expression, reprogramming efficiency, and X-
inactivation [35]. These observations indicate that the
Matsumoto et al. Orphanet Journal of Rare Diseases 2013, 8:190 Page 12 of 14
http://www.ojrd.com/content/8/1/190specific iPS cell derivation conditions may significantly
affect the ability to generate iPS cell lines particularly if a
disease mutation affects cell fate stability. Second, our
study applies the FOP iPS cells as a disease model to dem-
onstrate a potential function for ACVR1 in chondrogene-
sis and mineralization. These two endpoints may be useful
for screening drug modulators that target different stages
of human osteogenesis, particularly once the chondro-
genic potential of the episomal iPS cells has been deter-
mined. Further studies to identify if cell fate stability is
affected in non-pluripotent cells such as chondrocytes or
osteoblasts may also reveal if cell fate plays a key role in
the pathogenesis of heterotopic ossification in FOP.Conclusions
Our iPS cell strategy provides a key first step towards dis-
secting the cellular and molecular mechanisms of human
skeletal disease pathogenesis in FOP. Human iPS cells will
also be a valuable tool that reflects the diversity of patients
we see in the clinic since patients, and thus, their iPS cells
show clinical variability, genetic background effects, and
epigenetic influences. Creation of new isogenic controls by
gene correction [36], combined with translational genetic
studies and correlations with murine models, provides ex-
citing venues for new strategies to understand the stages
of normal and pathologic human skeletal development.
Our studies demonstrate the creation of iPS cells from pa-
tients with FOP, identify that ACVR1 may have a new role
in regulating mineralization activity, and provide a proof-
of-concept for further development of human iPS cells as
disease models for studying human skeletal diseases.Additional files
Additional file 1: Table S1. Characteristics of the iPS cells used in this
study. This table summarizes the characterization results for the FOP and
control iPS cell lines used in this study and the original fibroblast source
numbers for the iPS cell lines.
Additional file 2: Figure S1. FOP dermal fibroblasts do not
spontaneously mineralize. (A) Human dermal fibroblasts (HDFs) from
patients with FOP are heterozygous for the ACVR1 R206H (617G > A)
mutation. (B) Primary human mesenchymal stem cells (MSCs) cultured in
mineralizing media for 12 days show an increase in von Kossa staining.
Mineralized deposits appear as the darker brown or black staining. The
light golden staining is background. Standard MSC maintenance medium
is used as a comparison for non-mineralizing conditions. (C) HDFs from
FOP donors do not mineralize (black staining) when cultured in mineralizing
medium for 18 days. Standard HDF medium without osteogenic supplements
is used as a comparison for non-mineralizing conditions.
Additional file 3: Table S2. Quantitative and RT-PCR primers used in
this study.
Additional file 4: Figure S2. Characterization of retroviral FOP iPS cells.
(A) Teratoma formation showing representatives of the three germ layers.
Scale bars = 200 μm. (B) Quantitative PCR gene expression analysis
showing expression of pluripotency markers by the iPS cells. Error bars
are average expression +/− 1 SD of technical triplicates. Gene expression
studies were repeated in triplicate.Additional file 5: Figure S3. Characterization of additional retroviral
FOP iPS cells. (A) Relative expression of retroviral transgenes in vFOP4-1,
vFOP4-3, and vFOP5-22 iPS cells analyzed by quantitative RT-PCR. The
value of each transgene 6 days after infection of wild-type dermal fibroblast
(DF 4 F D6) was set to 1, demonstrating suppression of transgene
expression. (B) Teratoma formation showing representatives of the three
germ layers. Scale bars = 200 μm. (C) Karyotypes of the vFOP4 and vFOP5
iPSC lines are normal. (D) RT-PCR gene expression analysis showing
expression of pluripotency markers by the iPS cells. (E) Quantitative PCR
gene expression analysis showing expression of RUNX2, SP7/OSX, and
OC genes during iPS cell mineralization culture. Error bars are average
expression +/− 1 SD of measurements pooled from vFOP4-1, vFOP4-3,
and vFOP5-22 iPS cell lines. n = 3 per time point. *, p < 0.05.
Additional file 6: Figure S4. Characterization of episomal iPS cell lines.
(A) FOP human dermal fibroblasts and the derived eFOP iPS cells have
normal karyotypes. (B) Teratoma formation showing representatives of
the three germ layers. b, bone; c, cartilage; g, primitive gut; m,
melanocytes; n, neuronal tube like structures. Line eFOP2-8 showed no
identifiable endodermal structures, and so was excluded from further
analysis. Black scale bar = 50 μm. (C) Quantitative RT-PCR analysis of
episomal transgene expression in the integration-free iPS cell lines. HDFs
electroporated with the episomal vectors are used to determine the
control levels of total mRNA present. Log10 scale. (D) Quantitative PCR
analysis of the EBNA gene in genomic DNA from the integration-free iPS
cell lines. Note that although episomal transgene expression of OCT4
was detectable in the eFOP3-4 cell line, the level is low and no EBNA
integration into the genome was detected.
Additional file 7: Figure S5. Immunohistochemistry of episomal iPS
cell colonies show expression of pluripotency markers NANOG, OCT3/4,
SSEA3, TRA1-60, and TRA1-81.
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